Patients recruited for phase I trials are considered to have a poor prognosis, because the
majority of them have already been heavily treated. We examined the survival of lung cancer …

Purpose: Historical data from pilot, Phase II, and Phase III studies for patients with advanced-
stage non-small cell lung cancer (NSCLC) were used to evaluate a statistical model …

Background. Patients with advanced or metastatic cancer treated in Phase I clinical trials are
considered to have a poor prognosis. Survival from first treatment in a Phase I trial was …

This study was designed to compare the outcome of stage IIIB/IV non-small cell lung cancer
patients who were treated with chemotherapy but did not participate in clinical trials of first …

PURPOSE: To determine the changes in clinical trials and outcomes of patients with
advanced-stage non–small-cell lung cancer (NSCLC) treated on phase III randomized trials …

The published reports of phase I clinical trials of anticancer agents conducted in Japan from
1981 to 1991 were reviewed. A total of 56 clinical studies that evaluated 38 different agents …

This is a comment on" Response rate as an endpoint for evaluating new cytotoxic agents in
phase II trials of non-small-cell lung cancer." Ann Oncol. 1998 Oct; 9 (10): 1079-84. This is a …

Background Selecting patients for phase I trials in order to investigate cytotoxic agents is
challenging, since there is no clear and reliable guidance to estimate life expectancy among …

Background Response rate (RR) has been used as a defining endpoint of new-agent phase
II trials for non-small-cell lung cancer (NSCLC). However, tumor responses to chemotherapy …

PURPOSE The goals of this study were to analyze and compare the major clinical response
rates and survival of patients with either measurable or assessable disease status to …